Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-1101 in Granuloma Annulare
NCT05580042Phase 1Completed
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INN-04-01 in granuloma annulare (GA), sponsored by TWi Biotechnology, Inc. Primary endpoints: Treatment Emergent Adverse Events up to 6 weeks, Number of subjects with abnormal vital signs up to 6 weeks and 3 more. Started Oct 2022; status: completed.
02
Drugs
INN-04-01
03
Conditions
granuloma annulare (GA)
Beyond the preview
Go deeper on NCT05580042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580042.